Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Acute myeloid leukemia stories

Nov 17, 2026

Sellas cancer vaccine significantly extends survival in AML trial

Sellas Life Sciences reported its experimental vaccine for acute myeloid leukemia significantly reduced risk of death in a late-stage clinical trial, sending shares to a record single-day surge. The unexpected positive result offers new hope for a difficult-to-treat blood cancer.

Nov 17, 2026·2 sources
00

Top claims

  • ▪STAT News biotech columnist Adam Feuerstein acknowledged on November 17, 2026, that his September 2026 prediction forecasting galinpepimut-S would fail to prolong survival in Phase 3 testing was incorrect
  • ▪Alliance Global Partners analyst James Molloy stated galinpepimut-S could secure expedited U.S. FDA approval as a monotherapy in 2027 and see off-label usage earlier in treatment paradigms
  • ▪Galinpepimut-S reduced the risk of death by 41% compared to standard best available treatment in advanced acute myeloid leukemia patients

Topics

Drug Policy, Pricing & ApprovalCancer immunotherapyHematology & Blood CancersClinical trialsClinical trial endpointsFDA drug approval processCancer treatment breakthroughsCancer & Oncology

Related entities

New York